Analysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX), Greenwich LifeSciences (GLSI) and ACELYRIN, INC. (SLRN)
HC Wainwright & Co. : The Poseida Therapeutics (PSTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.
Poseida Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target
Piper Sandler Reaffirms Their Buy Rating on Poseida Therapeutics (PSTX)
Poseida Therapeutics Analyst Ratings
Strong Buy Rating for Poseida Therapeutics Amidst Strategic Partnerships and Robust CAR-T Manufacturing Capabilities
Strategic Advancements and Favorable Deal Terms Reinforce Buy Rating for Poseida Therapeutics
Strategic Partnership Boosts Poseida Therapeutics' Solid Tumor Treatment Capabilities and Underpins Buy Rating
Poseida Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE), Poseida Therapeutics (PSTX) and Align Tech (ALGN)
Analysts Are Bullish on These Healthcare Stocks: Generation Bio (GBIO), Poseida Therapeutics (PSTX)
Poseida Therapeutics (PSTX) Gets a Buy From William Blair
Analysts Are Bullish on Top Healthcare Stocks: Poseida Therapeutics (PSTX), Lumos Pharma (LUMO)
Buy Rating for Poseida Therapeutics Amid Strong Financials and Promising Clinical Updates
Poseida Therapeutics Analyst Ratings
William Blair Sticks to Its Buy Rating for Poseida Therapeutics (PSTX)
Analysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX) and Rhythm Pharmaceuticals (RYTM)
BTIG Reaffirms Their Buy Rating on Poseida Therapeutics (PSTX)
Poseida Therapeutics (PSTX) Gets a Buy From BTIG